BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Embleton ND, Harkensee C, Mckean MC. Palivizumab for preterm infants. Is it worth it? Arch Dis Child Fetal Neonatal Ed 2005;90:F286-9. [PMID: 16036888 DOI: 10.1136/adc.2004.058081] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Yeo KT, Yung CF, Khoo PC, Saffari SE, Sng JSP, How MS, Quek BH. Effectiveness of Palivizumab Against Respiratory Syncytial Virus Hospitalization Among Preterm Infants in a Setting With Year-Round Circulation. J Infect Dis 2021;224:279-87. [PMID: 33274362 DOI: 10.1093/infdis/jiaa749] [Reference Citation Analysis]
2 González de Dios J, Ochoa Sangrador C. Conferencia de Consenso sobre bronquiolitis aguda (I): metodología y recomendaciones. Anales de Pediatría 2010;72:221.e1-221.e33. [DOI: 10.1016/j.anpedi.2009.11.020] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
3 Meberg A, Bruu AL. Respiratory syncytial virus infections in congenital heart defects--hospitalizations and costs. Acta Paediatr 2006;95:404-6. [PMID: 16720485 DOI: 10.1080/08035250500447944] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
4 Resch B. Palivizumab in preventing respiratory syncytial virus-related hospitalization in high-risk infants. Expert Rev Pharmacoecon Outcomes Res 2008;8:529-38. [PMID: 20528363 DOI: 10.1586/14737167.8.6.529] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
5 Lenney W. The future for lung disease in children. Thorax 2007;62:1021-2. [PMID: 18025133 DOI: 10.1136/thx.2007.090969] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
6 Gómez RS, Ramirez BA, Céspedes PF, Cautivo KM, Riquelme SA, Prado CE, González PA, Kalergis AM. Contribution of Fcγ receptors to human respiratory syncytial virus pathogenesis and the impairment of T-cell activation by dendritic cells. Immunology 2016;147:55-72. [PMID: 26451966 DOI: 10.1111/imm.12541] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
7 Park SK, Jung YJ, Yoo HS, Ahn SY, Seo HJ, Choi SH, Kim MJ, Jeon GW, Koo SH, Lee K, Chang YS, Park WS. Effect of Synagis® (palivizumab) prophylaxis on readmission due to respiratory syncytial virus in very low birth weight infants. Korean J Pediatr 2010;53:358. [DOI: 10.3345/kjp.2010.53.3.358] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
8 Tregoning JS, Schwarze J. Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clin Microbiol Rev 2010;23:74-98. [PMID: 20065326 DOI: 10.1128/CMR.00032-09] [Cited by in Crossref: 394] [Cited by in F6Publishing: 264] [Article Influence: 32.8] [Reference Citation Analysis]
9 Murray J, Saxena S, Sharland M. Preventing severe respiratory syncytial virus disease: passive, active immunisation and new antivirals. Arch Dis Child 2014;99:469-73. [PMID: 24464977 DOI: 10.1136/archdischild-2013-303764] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
10 Prescott WA, Doloresco F, Brown J, Paladino JA. Cost Effectiveness of Respiratory Syncytial Virus Prophylaxis: A Critical and Systematic Review. PharmacoEconomics 2010;28:279-93. [DOI: 10.2165/11531860-000000000-00000] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
11 Gomez RS, Guisle-Marsollier I, Bohmwald K, Bueno SM, Kalergis AM. Respiratory Syncytial Virus: pathology, therapeutic drugs and prophylaxis. Immunol Lett 2014;162:237-47. [PMID: 25268876 DOI: 10.1016/j.imlet.2014.09.006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
12 Taylor RS. Probiotics to prevent necrotizing enterocolitis: Too cheap and easy? Paediatr Child Health. 2014;19:351-352. [PMID: 25332671 DOI: 10.1093/pch/19.7.351] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
13 Rivera CA, Gómez RS, Díaz RA, Céspedes PF, Espinoza JA, González PA, Riedel CA, Bueno SM, Kalergis AM. Novel therapies and vaccines against the human respiratory syncytial virus. Expert Opinion on Investigational Drugs 2015;24:1613-30. [DOI: 10.1517/13543784.2015.1099626] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
14 Lewis L, Sinha I, Losty PD. Respiratory syncytial virus bronchiolitis in congenital diaphragmatic hernia: A systematic review of prevalence rates and palivizumab prophylaxis. Pediatr Pulmonol 2021. [PMID: 34617409 DOI: 10.1002/ppul.25717] [Reference Citation Analysis]
15 Fitzgerald DA. Viral bronchiolitis for the clinician. J Paediatr Child Health 2011;47:160-6. [PMID: 20500436 DOI: 10.1111/j.1440-1754.2010.01735.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
16 Boniche C, Rossi SA, Kischkel B, Barbalho FV, Moura ÁND, Nosanchuk JD, Travassos LR, Taborda CP. Immunotherapy against Systemic Fungal Infections Based on Monoclonal Antibodies. J Fungi (Basel) 2020;6:E31. [PMID: 32121415 DOI: 10.3390/jof6010031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
17 Homaira N, Rawlinson W, Snelling TL, Jaffe A. Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective. Int J Pediatr 2014;2014:571609. [PMID: 25548575 DOI: 10.1155/2014/571609] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 6.5] [Reference Citation Analysis]
18 Berger TM, Aebi C, Duppenthaler A, Stocker M; Swiss Pediatric Surveillance Unit. Prospective population-based study of RSV-related intermediate care and intensive care unit admissions in Switzerland over a 4-year period (2001-2005). Infection 2009;37:109-16. [PMID: 19412586 DOI: 10.1007/s15010-008-8130-z] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 2.8] [Reference Citation Analysis]
19 Adams M, Doull I. Management of bronchiolitis. Paediatr Child Health (Oxford) 2009;19:266-70. [PMID: 32288783 DOI: 10.1016/j.paed.2009.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
20 Lambkin-Williams R, Noulin N, Mann A, Catchpole A, Gilbert AS. The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics. Respir Res 2018;19:123. [PMID: 29929556 DOI: 10.1186/s12931-018-0784-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
21 Bush A, Thomson AH. Acute bronchiolitis. BMJ 2007;335:1037-41. [PMID: 18007004 DOI: 10.1136/bmj.39374.600081.AD] [Cited by in Crossref: 49] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]